| 32.07 -0.15 (-0.47%) | 07-17 15:48 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 39.34 | 1-year : | 41.42 |
| Resists | First : | 33.68 | Second : | 35.47 |
| Pivot price | 33.16 |
|||
| Supports | First : | 30.79 | Second : | 25.62 |
| MAs | MA(5) : | 31.96 |
MA(20) : | 33.11 |
| MA(100) : | 32.62 |
MA(250) : | 27.64  |
|
| MACD | MACD : | -0.5 |
Signal : | -0.3 |
| %K %D | K(14,3) : | 15.8 |
D(3) : | 12.6 |
| RSI | RSI(14): 42.6 |
|||
| 52-week | High : | 37.34 | Low : | 14.98 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ TEVA ] has closed above bottom band by 23.9%. Bollinger Bands are 7% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 32.5 - 32.71 | 32.71 - 32.91 |
| Low: | 31.01 - 31.28 | 31.28 - 31.53 |
| Close: | 31.79 - 32.23 | 32.23 - 32.62 |
Teva Pharmaceutical Industries Limited functions as a global pharmaceutical enterprise, involved in the conception, manufacturing, marketing, and provision of a broad spectrum of generic, specialty, and biopharmaceutical products throughout North America, Europe, and various international markets. The company's diverse product range includes sterile items, hormones, potent drugs, and cytotoxic agents, available in numerous forms like tablets, capsules, injectable solutions, inhalable preparations, liquids, transdermal patches, topical ointments, and creams. Additionally, Teva develops, produces, and sells active pharmaceutical ingredients (APIs). The firm prioritizes several key therapeutic domains: central nervous system disorders, pain management, respiratory ailments, and oncology. In the central nervous system sector, prominent products include Copaxone, intended for relapsing forms of multiple sclerosis; AJOVY, prescribed for preventing migraines; and AUSTEDO, which targets tardive dyskinesia and chorea linked to Huntington's disease. For respiratory conditions, Teva offers medications such as ProAir, QVAR, ProAir Digihaler, AirDuo Digihaler, ArmonAir Digihaler, BRALTUS, CINQAIR/CINQAERO, DuoResp Spiromax, and AirDuo RespiClick/ArmonAir RespiClick, all designed to treat asthma and chronic obstructive pulmonary disease. The oncology portfolio features therapies like Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim. Teva Pharmaceutical Industries Limited is also engaged in a collaboration with MedinCell to advance and commercialize multiple long-acting injectable formulations, notably a risperidone suspension for individuals affected by schizophrenia. The company was established in 1901 and its primary headquarters are located in Tel Aviv-Yafo, Israel.
Fri, 17 Jul 2026
Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Thu, 16 Jul 2026
Teva snaps seven straight sessions of losses (TEVA:NYSE) - Seeking Alpha
Wed, 15 Jul 2026
Diversify Wealth Management LLC Buys 54,488 Shares of Teva Pharmaceutical Industries Ltd. $TEVA - MarketBeat
Tue, 14 Jul 2026
Teva Pharmaceutical Industries (TEVA) Advances TEV 408, Is The Stock Still Cheap? - Sahm
Tue, 14 Jul 2026
Teva Pharmaceutical Industries (TEVA) Could Be 21% Below Fair Value On Vitiligo Trial Progress - Yahoo Finance
Mon, 13 Jul 2026
US appeals court revives Teva lawsuit over Lilly osteoporosis drug - Reuters
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NYSE
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
| Shares Out | 1,160 (M) |
| Shares Float | 1,080 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 62.4 (%) |
| Shares Short | 32,030 (K) |
| Shares Short P.Month | 33,870 (K) |
| EPS | 1.34 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 7.07 |
| Profit Margin | 9 % |
| Operating Margin | 19.1 % |
| Return on Assets (ttm) | 6.3 % |
| Return on Equity (ttm) | 21.6 % |
| Qtrly Rev. Growth | 2.2 % |
| Gross Profit (p.s.) | 7.78 |
| Sales Per Share | 14.95 |
| EBITDA (p.s.) | 4.31 |
| Qtrly Earnings Growth | 72.1 % |
| Operating Cash Flow | 1,710 (M) |
| Levered Free Cash Flow | 2,610 (M) |
| PE Ratio | 23.92 |
| PEG Ratio | 0.9 |
| Price to Book value | 4.53 |
| Price to Sales | 2.14 |
| Price to Cash Flow | 21.74 |
| Dividend | 0.09 |
| Forward Dividend | 0 |
| Dividend Yield | 0.2% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|